Madrid
Updated:
Keep
The Infanta Leonor University Hospital has participated in an international clinical trial that shows that the administration of the antiviral drug Remdesivir intravenously during the three days following the diagnosis of COVID-19 reduces by 87% the risk of hospitalization and death in susceptible vulnerable patients to suffer from the disease in a serious way. The study was recently published in ‘The New England Journal of Medicine‘, one of the most prestigious publications in the world, and has had the collaboration of numerous services of this hospital and researchers from various disciplines.
This is a randomized, double-blind, placebo-controlled trial of intravenous Remdesivir in non-hospitalized patients with risk factors for disease progression within 7 days of the onset of COVID-19 symptoms.
The study involved 562 patients (10 recruited at the Infanta Leonor University Hospital) over 60 years of age who are at high risk of passing COVID-19 severely for different reasons, such as suffering from diabetes, obesity, hypertension, cancer, cardiovascular or cerebrovascular disease, immunosuppression, chronic kidney disease, chronic liver disease, or chronic lung disease.
These patients randomly received Remdesivir or placebo for three days. 279 received Remdesivir and 283 placebo. The results of the study with the antiviral show an 87% reduction in hospitalization related to COVID or death from any cause.
The recently published study reaffirms the efficacy of this antiviral in reducing the complications of SARS-CoV-2 infection, since of the 279 patients who received this drug, only 2 (0.7% of the total) suffered admission compared to 15 patients (5.4% of the total) of the 283 who were part of the control group and who were administered placebo.
As argued by the main researcher and co-author of the study of the Internal Medicine Service of the Infanta Leonor University Hospital, Pablo Ryan, the efficacy of antiviral treatment with Remdesivir has been demonstrated in reducing the complications of SARS-CoV-2 infection and, therefore, it might be a very good tool to prevent care pressure in hospitals and in the ICU.
.
.
